| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17460441.2016.1243525 |
| P698 | PubMed publication ID | 27700193 |
| P2093 | author name string | Sabino De Placido | |
| Roberto Bianco | |||
| Roberta Rosa | |||
| Valentina D'Amato | |||
| P2860 | cites work | Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease | Q44278315 |
| Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients | Q45340032 | ||
| Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase | Q45760359 | ||
| Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. | Q46107456 | ||
| Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency | Q46174937 | ||
| Unexpectedly similar rates of nucleotide substitution found in male and female hominids | Q47836425 | ||
| A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors | Q51297641 | ||
| Epitope landscape in breast and colorectal cancer | Q51894674 | ||
| Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients | Q21284707 | ||
| Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin | Q24299768 | ||
| Wnt4 inhibits cell motility induced by oncogenic Ras | Q24299974 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 | ||
| Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal | Q26744536 | ||
| Wnt Signaling in Cancer Stem Cell Biology | Q26746101 | ||
| Cancer stem cells and immunoresistance: clinical implications and solutions | Q26769757 | ||
| Cancer stem cells: a metastasizing menace! | Q26771651 | ||
| Immune responses to human cancer stem-like cells/cancer-initiating cells | Q26781794 | ||
| Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28 | Q26991723 | ||
| Cellular signaling and biological functions of R-spondins | Q27023891 | ||
| Identification and expansion of human colon-cancer-initiating cells | Q27860627 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy | Q28082914 | ||
| Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits | Q28237197 | ||
| EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential | Q28484249 | ||
| The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma | Q28744417 | ||
| Metastasis: from dissemination to organ-specific colonization | Q29614295 | ||
| The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype | Q29615563 | ||
| Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma | Q29615607 | ||
| WNT signalling pathways as therapeutic targets in cancer | Q29615666 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| Cells of origin in cancer | Q29619557 | ||
| Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model | Q33616264 | ||
| Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. | Q33646227 | ||
| Emerging role of nanog in tumorigenesis and cancer stem cells | Q33786554 | ||
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer | Q33875120 | ||
| A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast | Q33914381 | ||
| Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis | Q33951212 | ||
| Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells | Q33971668 | ||
| Efficacy and safety of vismodegib in advanced basal-cell carcinoma. | Q34032213 | ||
| Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms | Q34075584 | ||
| Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia | Q34096825 | ||
| Epigenetic targeting of ovarian cancer stem cells | Q34135466 | ||
| Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship | Q34193347 | ||
| Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors | Q34323825 | ||
| Cavity-free plasmonic nanolasing enabled by dispersionless stopped light | Q34349143 | ||
| Ionizing radiation induces stemness in cancer cells | Q34395869 | ||
| A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. | Q34443946 | ||
| Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy | Q34448718 | ||
| CD73 is associated with poor prognosis in high-grade serous ovarian cancer | Q38835904 | ||
| Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters | Q38920037 | ||
| MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer | Q39016680 | ||
| CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist | Q39033543 | ||
| Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer | Q39066733 | ||
| Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance | Q39070920 | ||
| Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines | Q39097543 | ||
| Calyxin Y induces hydrogen peroxide-dependent autophagy and apoptosis via JNK activation in human non-small cell lung cancer NCI-H460 cells | Q39133347 | ||
| Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. | Q39279366 | ||
| ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness | Q39442395 | ||
| Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. | Q39630008 | ||
| Kinome profiling in pediatric brain tumors as a new approach for target discovery | Q39830889 | ||
| Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. | Q39883131 | ||
| MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. | Q39996214 | ||
| Measurement of interaction between antiprotons | Q40357137 | ||
| PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. | Q40509393 | ||
| Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma | Q41508355 | ||
| Tackling the cancer stem cells - what challenges do they pose? | Q34523263 | ||
| Suppression of cancer relapse and metastasis by inhibiting cancer stemness | Q35090120 | ||
| Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma | Q35117549 | ||
| MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1 | Q35140218 | ||
| Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells | Q35176428 | ||
| Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells | Q35176432 | ||
| PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting | Q35260766 | ||
| Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs | Q35280672 | ||
| Can we safely target the WNT pathway? | Q35591995 | ||
| MUC1 immunobiology: from discovery to clinical applications | Q35671712 | ||
| Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells | Q35678417 | ||
| Filtering promiscuous compounds in early drug discovery: is it a good idea? | Q35924688 | ||
| TEX11 is mutated in infertile men with azoospermia and regulates genome-wide recombination rates in mouse. | Q36057591 | ||
| TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer | Q36638173 | ||
| Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma | Q36772125 | ||
| The sonic hedgehog signaling network in development and neoplasia | Q36918590 | ||
| Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway | Q37134040 | ||
| Src and focal adhesion kinase as therapeutic targets in cancer | Q37215683 | ||
| Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. | Q37320359 | ||
| Normal stem cells and cancer stem cells: similar and different | Q37740620 | ||
| TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. | Q37880150 | ||
| Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers | Q37966605 | ||
| The developing cancer stem-cell model: clinical challenges and opportunities | Q37980960 | ||
| Regulation of EMT by Notch signaling pathway in tumor progression | Q38156210 | ||
| Therapeutic modulation of Notch signalling--are we there yet? | Q38208211 | ||
| Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Q38262473 | ||
| Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 | ||
| Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer | Q38309242 | ||
| Clusterin Mediates TGF-β–Induced Epithelial–Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells | Q38322593 | ||
| Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer | Q38348851 | ||
| A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia | Q38387402 | ||
| Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins | Q38483070 | ||
| Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. | Q38485521 | ||
| CYLD regulates keratinocyte differentiation and skin cancer progression in humans. | Q38626355 | ||
| An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. | Q38785671 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplastic stem cells | Q1638475 |
| P304 | page(s) | 1201-1212 | |
| P577 | publication date | 2016-10-04 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Approaches for targeting cancer stem cells drug resistance | |
| P478 | volume | 11 |
| Q90737495 | Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse |
| Q52721498 | Current Opinions on Chemoresistance: An Overview |
| Q41352333 | Gene Expression Profiling of Hepatocellular Carcinoma Derived Cancer Stem Like Cell under Hypoxia. |
| Q42135646 | Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells |
| Q46262914 | Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. |
| Q58719363 | Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy |
| Q89638333 | Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells |
| Q61816938 | Selected Office Based Anticancer Treatment Strategies |
| Q92134544 | The Role of Exosomal microRNA in Cancer Drug Resistance |
Search more.